Cryptococcosis is an important opportunistic infection that causes more than 100,000 HIV-related deaths each year. It was named the Busse-Buschke disease because of its first description by Otto Busse and Abraham Buschke in 1894.
Even though the infection is usually HIV-related, in many centers (especially in developed countries), most of the non-HIV-related cases include patients under immunosuppressive treatments or with organic failure syndromes, transplants, innate immunological problems, common variable immunodeficiency syndrome, and hematological disorders.
There are more than 50 species of Cryptococcus; C. neoformans and C. gattii cause the majority of infections, and some consider them the only pathogens in humans.
C. neoformans is an encapsulated yeast that can be found in aged pigeon droppings which causes mild infections, from airway colonization or asymptomatic ones in laboratory workers to severe infections like meningitis or disseminated disease. It is the most common species from the Cryptococcus genre in our region (Brazil) and other temperate weathers around the world. 
The major predisposing factor to cryptococcal infection is HIV; however, the predisposing factors in non-HIV patients are as follows:
Syndromes and Autoantibodies
Approximately 1 million cases of cryptococcal meningitis are reported annually. The incidence have markedly increased since 1950s because of corticosteroid use and improvement of survival in cancer patients. However, most of the cryptococcal reports come from the 1980s and are predominantly AIDS-related cases. Approximately 6% of patients with AIDS develop cryptococcal infections, and patients with AIDS-associated cryptococcosis account for 85% of all patients diagnosed with cryptococcosis. 
The organism is acquired by inhalation. After being deposited into the pulmonary alveoli, the yeast spores must survive the normal to high pH and the physiological concentrations of carbon dioxide before they are phagocytized by alveolar macrophages, a more acidic environment, and disseminated after a latent period of containment in the lung lymph nodes. The essential factor in the survival of C. neoformans in this extracellular environment is glucosylceramide synthase. 
The host response includes both cellular and humoral components. Possibly, the eradication of Cryptococci relies on natural killer cells and antibody-dependent cell-mediated killing. 
While all organs can be involved, Cryptococcus spp. have a strong affinity for the central nervous system. This neurotropism is linked to several cryptococcal-specific factors which facilitate the permeability of the blood-brain barrier; between them, metalloproteinases and ureases enzymes cause neuromodulation and mechanisms facilitate survival in the nutrient-deprived environment of the brain (autophagy and high-affinity sugar transporters). 
There can be little or no necrosis or organ damage until later disease. In patients with heavy infections, organ dysfunction may be accelerated, primarily due to tissue distortion caused by the growing fungal burden. 
C. neoformans reproduces by budding and forms round yeast-like cells that are 3 to 6 micrometers in diameter. In the host and culture media, each cell is surrounded by a large polysaccharide capsule that has antiphagocytic properties and may be immunosuppressive. It can form smooth, convex, yellow, or tan colonies on solid media at 20 to 37 degrees C. The non-pathogenic strains do not grow at this temperature. 
Cryptococcal meningitis usually presents as a subacute meningoencephalitis. The patient commonly presents with neurological symptoms such as a headache, altered mental status, and other signs and symptoms include lethargy along with fever, stiff neck (both associated with an aggressive inflammatory response), nausea and vomiting. Some patients who are HIV positive may have minimal or nonspecific symptoms at presentation.
The duration of symptoms from onset to a presentation is usually 1 to 2 weeks in HIV cases and 6 to 12 weeks in non-HIV cases.
Visual symptoms include diplopia and photophobia at the onset, and reduced acuity later in the disease (due to high cerebrospinal fluid (CSF) pressure or compression of the optic nerve and tracts). Other findings include hearing defects, ataxia, aphasia, seizures, and chorea.
Although C. neoformans enters the body through the lungs, the central nervous system (CNS) is the main site of evident clinical infection. 
The workup at initial evaluation should depend on CSF lab tests. However, to prevent a post-dural puncture cerebral herniation, a CT scan or MRI of the brain or a fundus examination should be considered before performing a lumbar puncture. 
Blood and CSF should be cultured for fungi and tested for cryptococcal antigen. Routine lab tests may be normal even with widespread disease. Opening pressure has to be measured at the first spinal tap, a pressure over 25 cm of water is a predictor of a poor prognosis. 
CSF usually presents low glucose and high protein levels. White cell count can be normal or higher than 20 microL and have a lymphocyte predominance. Nevertheless, CSF can be normal and have positive results on India ink stain and antigen testing (especially in HIV-positive patients who do not have an adequate inflammatory response). 
Treatment has not varied for a decade, according to recommendations from the 2010 IDSA (Infectious Diseases Society of America) update. The first-line antifungal treatment is based on the induction, consolidation, and maintenance of the following three types of patients:
Transplant Related Disease
Not HIV/Transplant Related Disease
The combination of amphotericin B and flucytosine has proved the most effective measure to clear the infection, and it showed a greater survival benefit over amphotericin alone. However, due to its cost, flucytosine is often unavailable in poor-resource settings where the disease burden is significant. Combinations of amphotericin B and fluconazole have been studied, and greater results have been found over amphotericin B alone. ,,
Without treatment, the clinical course progresses to confusion, seizures, reduced level of consciousness, and coma.
Headache refractory to pain-killers can be treated with spinal decompression after an adequate neuroimaging evaluation with a CT scan or MRI. The safe maximum volume of CSF that can be drained at one lumbar puncture is unclear, but up to 30 mL are frequently removed with the pressure checked after each 10 mL removed. ,
The differential diagnosis is based upon the following causes of intracranial mass lesions and infections:
Mortality varies from country to country depending on the resource settings. It remains high in the United States and France, with a 10-week mortality of 15% to 26%, and it is even higher in non-HIV patients because of the delayed diagnosis and dysfunctional immune responses. On the other hand, in poor-resource countries, mortality increase from 30% to 70% in 10 weeks because of the late presentation and lack of access to drugs, manometers, and optimal monitoring.
Complications include the following:
Cerebral cryptococcomas can cause significant short- and long-term neurological complications. They are hard to treat and normally require a long-term antifungal therapy.
Hydrocephalus is a later complication and can present as dementia or chronic headache.
The definitive diagnosis of cryptococcal meningitis is made by culture from the CSF. The opening pressure should be measured along with India ink evaluation, cryptococcal antigen testing, fungal culture, and routine spinal fluid studies. A positive cryptococcal antigen in the CSF or serum can strongly suggest the infection before the cultures become positive in high-risk patients.
Neuroimaging must be performed prior to lumbar puncture if there is a concern for a high intracranial pressure.
The principal antifungal agents for the treatment of cryptococcal meningitis are intravenous amphotericin B deoxycholate and its lipid formulations, oral flucytosine, and oral fluconazole. While amphotericin B and flucytosine are fungicidal, fluconazole is only fungistatic. Lipid formulations of amphotericin B are preferred on patients with renal dysfunction or at risk for renal failure.
Cryptococcal meningitis is fatal if untreated. The therapeutic regime includes three phases: Induction followed by consolidation for a total of 10 weeks (to rapidly sterilize the CSF and to decrease early mortality) and maintenance therapy to prevent relapses.
|||May RC,Stone NR,Wiesner DL,Bicanic T,Nielsen K, Cryptococcus: from environmental saprophyte to global pathogen. Nature reviews. Microbiology. 2016 Feb [PubMed PMID: 26685750]|
|||Pappas PG, Cryptococcal infections in non-HIV-infected patients. Transactions of the American Clinical and Climatological Association. 2013 [PubMed PMID: 23874010]|
|||Takahara DT,Lazéra Mdos S,Wanke B,Trilles L,Dutra V,Paula DA,Nakazato L,Anzai MC,Leite Júnior DP,Paula CR,Hahn RC, First report on Cryptococcus neoformans in pigeon excreta from public and residential locations in the metropolitan area of Cuiabá, State of Mato Grosso, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo. 2013 Nov-Dec [PubMed PMID: 24213188]|
|||Williamson PR,Jarvis JN,Panackal AA,Fisher MC,Molloy SF,Loyse A,Harrison TS, Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nature reviews. Neurology. 2017 Jan [PubMed PMID: 27886201]|
|||Rittershaus PC,Kechichian TB,Allegood JC,Merrill AH Jr,Hennig M,Luberto C,Del Poeta M, Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. The Journal of clinical investigation. 2006 Jun [PubMed PMID: 16741577]|
|||Schmidt S,Zimmermann SY,Tramsen L,Koehl U,Lehrnbecher T, Natural killer cells and antifungal host response. Clinical and vaccine immunology : CVI. 2013 Apr [PubMed PMID: 23365210]|
|||Vu K,Tham R,Uhrig JP,Thompson GR 3rd,Na Pombejra S,Jamklang M,Bautos JM,Gelli A, Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. mBio. 2014 Jun 3 [PubMed PMID: 24895304]|
|||Stie J,Fox D, Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology (Reading, England). 2012 Jan [PubMed PMID: 21998162]|
|||Perfect JR,Bicanic T, Cryptococcosis diagnosis and treatment: What do we know now. Fungal genetics and biology : FG [PubMed PMID: 25312862]|
|||Nyazika TK,Hagen F,Meis JF,Robertson VJ, Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. The Journal of infection. 2016 Jun [PubMed PMID: 27038502]|
|||Abassi M,Boulware DR,Rhein J, Cryptococcal Meningitis: Diagnosis and Management Update. Current tropical medicine reports. 2015 Jun 1 [PubMed PMID: 26279970]|
|||Perfect JR,Dismukes WE,Dromer F,Goldman DL,Graybill JR,Hamill RJ,Harrison TS,Larsen RA,Lortholary O,Nguyen MH,Pappas PG,Powderly WG,Singh N,Sobel JD,Sorrell TC, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 Feb 1 [PubMed PMID: 20047480]|
|||Day JN,Chau TTH,Wolbers M,Mai PP,Dung NT,Mai NH,Phu NH,Nghia HD,Phong ND,Thai CQ,Thai LH,Chuong LV,Sinh DX,Duong VA,Hoang TN,Diep PT,Campbell JI,Sieu TPM,Baker SG,Chau NVV,Hien TT,Lalloo DG,Farrar JJ, Combination antifungal therapy for cryptococcal meningitis. The New England journal of medicine. 2013 Apr 4 [PubMed PMID: 23550668]|
|||Campitelli M,Zeineddine N,Samaha G,Maslak S, Combination Antifungal Therapy: A Review of Current Data. Journal of clinical medicine research. 2017 Jun [PubMed PMID: 28496543]|
|||Merry M,Boulware DR, Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Jun 15 [PubMed PMID: 27009249]|
|||Beardsley J,Wolbers M,Kibengo FM,Ggayi AB,Kamali A,Cuc NT,Binh TQ,Chau NV,Farrar J,Merson L,Phuong L,Thwaites G,Van Kinh N,Thuy PT,Chierakul W,Siriboon S,Thiansukhon E,Onsanit S,Supphamongkholchaikul W,Chan AK,Heyderman R,Mwinjiwa E,van Oosterhout JJ,Imran D,Basri H,Mayxay M,Dance D,Phimmasone P,Rattanavong S,Lalloo DG,Day JN, Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. The New England journal of medicine. 2016 Feb 11 [PubMed PMID: 26863355]|
|||Panackal AA,Wuest SC,Lin YC,Wu T,Zhang N,Kosa P,Komori M,Blake A,Browne SK,Rosen LB,Hagen F,Meis J,Levitz SM,Quezado M,Hammoud D,Bennett JE,Bielekova B,Williamson PR, Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS pathogens. 2015 May [PubMed PMID: 26020932]|
|||Jitmuang A,Panackal AA,Williamson PR,Bennett JE,Dekker JP,Zelazny AM, Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis. Journal of clinical microbiology. 2016 Feb [PubMed PMID: 26607986]|
|||Vidal JE,Gerhardt J,Peixoto de Miranda EJ,Dauar RF,Oliveira Filho GS,Penalva de Oliveira AC,Boulware DR, Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort. Diagnostic microbiology and infectious disease. 2012 May [PubMed PMID: 22578940]|